BridgeBio Pharma, Inc. (BBIO) on GreekSoup https://greeksoup.ai/stocks/us/bbio/ Every dated entry in the public record on BridgeBio Pharma, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 BridgeBio Pharma, Inc.: Schedule 13G filed by BlackRock, Inc., 5.1% of the classhttps://greeksoup.ai/stocks/us/bbio/holders/us:BBIO:schedule-13:2026-10-27:bfc6fdadc7Tue, 27 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: short interest 19,997,556 shares at the 15 October 2026 settlement, 7.68 days to coverhttps://greeksoup.ai/stocks/us/bbio/short-interest/us:BBIO:short-interest:2026-10-15:86211c610bThu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/bbio/filings/us:BBIO:filing:2026-10-13:8af126461fTue, 13 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Gilbert Cisneros (CA31) disclosed a sale (partial), $1,001 - $15,000, traded 29 September 2026https://greeksoup.ai/stocks/us/bbio/congress/us:BBIO:congress:2026-10-12:b3e72b598bMon, 12 Oct 2026 00:00:00 +0000House tradeHouse trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: short interest 19,671,292 shares at the 30 September 2026 settlement, 5.85 days to coverhttps://greeksoup.ai/stocks/us/bbio/short-interest/us:BBIO:short-interest:2026-09-30:b8c367d065Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer), by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee., sold 8,721 shares (under a trading plan set in advance) at $69.01 on 17 September 2026, $601,868https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-09-21:9822b7c22eMon, 21 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer), by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee., sold 1,279 shares (under a trading plan set in advance) at $69.57 on 17 September 2026, $88,980https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-09-21:3024976a90Mon, 21 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: short interest 21,549,349 shares at the 15 September 2026 settlement, 10.54 days to coverhttps://greeksoup.ai/stocks/us/bbio/short-interest/us:BBIO:short-interest:2026-09-15:a99000c449Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/bbio/filings/us:BBIO:filing:2026-08-31:84a247d79fMon, 31 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: short interest 21,845,899 shares at the 31 August 2026 settlement, 11.18 days to coverhttps://greeksoup.ai/stocks/us/bbio/short-interest/us:BBIO:short-interest:2026-08-31:65e2915ad2Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer), by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee., sold 8,100 shares (under a trading plan set in advance) at $83.86 on 19 August 2026, $679,256https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-20:8b5d5a5bdaThu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer), by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee., sold 1,800 shares (under a trading plan set in advance) at $84.69 on 19 August 2026, $152,436https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-20:cc09d45c3dThu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer), by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee., sold 100 shares (under a trading plan set in advance) at $85.65 on 19 August 2026, $8,565https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-20:211d8d3915Thu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer) sold 1,900 shares (under a trading plan set in advance) at $81.15 on 18 August 2026, $154,184https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-20:0acd3d9c2eThu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer) sold 17,279 shares (under a trading plan set in advance) at $82.21 on 18 August 2026, $1.4 millionhttps://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-20:6241e1699eThu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer) sold 14,602 shares (under a trading plan set in advance) at $82.99 on 18 August 2026, $1.2 millionhttps://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-20:b0f31498beThu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Kumar Neil (Chief Executive Officer) sold 1,199 shares (under a trading plan set in advance) at $83.77 on 18 August 2026, $100,444https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-20:a8cc71e62eThu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Form 144, KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 plans to sell 30,000 shares worth $2.5 million around 19 August 2026https://greeksoup.ai/stocks/us/bbio/planned-sales/us:BBIO:planned-sale:2026-08-19:d67ea88793Wed, 19 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Form 144, NEIL KUMAR plans to sell 34,980 shares worth $2.8 million around 18 August 2026https://greeksoup.ai/stocks/us/bbio/planned-sales/us:BBIO:planned-sale:2026-08-18:d99356e5dbTue, 18 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc. filed 8-K: material agreement, other eventshttps://greeksoup.ai/stocks/us/bbio/filings/us:BBIO:filing:2026-08-17:d28371a2d8Mon, 17 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Form 144, RANDAL SCOTT plans to sell 21,501 shares worth $1.7 million around 17 August 2026https://greeksoup.ai/stocks/us/bbio/planned-sales/us:BBIO:planned-sale:2026-08-17:5c8455b9c1Mon, 17 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Schedule 13D/A filed by KKR Genetic Disorder L.P., 4.7% of the classhttps://greeksoup.ai/stocks/us/bbio/holders/us:BBIO:schedule-13:2026-08-17:a991cbc373Mon, 17 Aug 2026 00:00:00 +0000Schedule 13D/13GItem 4 of the Schedule 13D is hereby amended and supplemented as follows: Sale of Common Stock On August 13, 2026, KKR Genetic Disorder L.P., as a selling stockholder, and the Issuer entered into an underwriting agreement (the ''Underwriting Agreement'') with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC (the ''Representatives''), as the representatives of the several underwriters listed on Schedule I thereto (the ''Underwriters''), relating to an offering of 5,000,000 shares of Common Stock by KKR Genetic Disorder L.P. (the ''Offering''), and purchase

Schedule 13D/13G. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: short interest 23,324,059 shares at the 14 August 2026 settlement, 10.79 days to coverhttps://greeksoup.ai/stocks/us/bbio/short-interest/us:BBIO:short-interest:2026-08-14:2e7845089cFri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc. Q2 FY2026 results: revenue $244 million, net income -$152 millionhttps://greeksoup.ai/stocks/us/bbio/results/fy2026-q2/us:BBIO:result:2026-08-10:aa8fdbc84dMon, 10 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/bbio/filings/us:BBIO:filing:2026-08-10:755abf34fcMon, 10 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/bbio/filings/us:BBIO:filing:2026-08-10:bc98facb2cMon, 10 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Schedule 13G/A filed by Farallon Capital Management, L.L.C., 5.5% of the classhttps://greeksoup.ai/stocks/us/bbio/holders/us:BBIO:schedule-13:2026-08-03:df306c184cMon, 03 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: Apuli Maricel (Chief Accounting Officer) sold 2,000 shares (under a trading plan set in advance) at $80.06 on 30 July 2026, $160,120https://greeksoup.ai/stocks/us/bbio/insiders/us:BBIO:insider:2026-08-03:c462c9c1b3Mon, 03 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> BridgeBio Pharma, Inc.: short interest 23,342,623 shares at the 31 July 2026 settlement, 11.50 days to coverhttps://greeksoup.ai/stocks/us/bbio/short-interest/us:BBIO:short-interest:2026-07-31:06435d28e6Fri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>